-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

Benzinga·10/07/2026 17:14:56
Listen to the news
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $87 to $85.